References in periodicals archive ?
The project in Charlton represents the first major expansion for rEVO since 2009 when it lauched sales of ATryn for patients with an inherited deficiency in the anti-clotting agent antithrombin III.
commercialization rights to ATryn, a drug intended to prevent blood clots, from Lundbeck Inc.
ATryn, a recombinant form of human antithrombin developed by GTC Biotherapeutics, was approved by the FDA for the prevention of peri-operative and peri-partum thromboembolic events in hereditary antithrombin deficient patients.
Atryn aims to prevent excessive blood clots in patients with a disorder known as hereditary antithrombin deficiency.
ATryn is partnered with LEO Pharma A/S for development and commercialization in Europe, Canada, and the Middle East.
rEVO Biologics announced today the results of a major retrospective study analysis of its pivotal phase 3 studies which demonstrate that pregnant patients with hereditary antithrombin deficiency (HD) benefit from ATryn Antithrombin (Recombinant) therapy to prevent venous thromboembolic events (VTE).
Yet bringing ATryn, an agent to regulate clotting in people with an inherited deficiency in the blood protein Antithrombin III, to market came with a cost.
As well, we have made progress towards our goal of improving the profitability of ATryn, with the recently announced return of U.
s (Framingham MA) experimental anticlotting therapy, called Atryn, is made using a human protein gathered from female goats bred to produce it in their milk.
rEVO Biologics announced today that hereditary antithrombin (AT) deficiency, and the use of the company's lead product ATryn Antithrombin (Recombinant), in the successful treatment of a pregnant patient with hereditary AT deficiency to prevent thromboembolic events (blood clots) is the focus of a TV segment on Behind the Mystery: Rare and Genetic Diseases, the ground breaking series on The Balancing Act[TM], America's premier morning show that airs weekday mornings on Lifetime Television.
FRAMINGHAM - ATryn, the first approved drug made in the milk of genetically altered animals, has gone on sale in the United States, GTC Biotherapeutics Inc.
rEVO Biologics announced today that hereditary antithrombin (AT) deficiency, and the use of the company's lead product ATryn antithrombin (Recombinant), will be the focus of a TV segment on Behind the Mystery: Rare and Genetic Diseases, the ground breaking series on The Balancing Act[TM], America's premier morning show that airs weekday mornings on Lifetime Television.
Dictionary browser ?
- atrium sinistrum
- Atropa belladonna
- atrophic arthritis
- atrophic rhinitis
- atropine sulfate
- Att. Gen.
- attach to
- attaché case
- Attached column
- attachment disorder
- attachment of earnings
- attack ad
Full browser ?
- Atrovent HFA
- Atrovent HFA
- ATRRS Funding Allocation Model
- ATS Account
- ATS Accounts
- ATS Facilities Notification
- ATS Message Handling System
- ATS R&D IPT
- ATS route